Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.

Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Rédini F, Ory B, Heymann D.

Cancer Lett. 2014 Mar 28;344(2):291-8. doi: 10.1016/j.canlet.2013.11.017. Epub 2013 Dec 11.

PMID:
24333720
[PubMed - indexed for MEDLINE]
2.

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.

PLoS One. 2012;7(5):e37431. doi: 10.1371/journal.pone.0037431. Epub 2012 May 25.

PMID:
22662154
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.

Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN.

Oncotarget. 2012 Nov;3(11):1416-27.

PMID:
23232026
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.

Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.

PLoS One. 2013;8(3):e59879. doi: 10.1371/journal.pone.0059879. Epub 2013 Mar 22.

PMID:
23533654
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O.

Clin Cancer Res. 2011 Apr 15;17(8):2373-84. doi: 10.1158/1078-0432.CCR-10-2289. Epub 2011 Mar 3.

PMID:
21372221
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.

Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T.

Oncol Rep. 2011 Nov;26(5):1273-9. doi: 10.3892/or.2011.1370. Epub 2011 Jul 1.

PMID:
21725613
[PubMed - indexed for MEDLINE]
7.

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C, Maity A.

Mol Pharmacol. 2012 Dec;82(6):1230-40. doi: 10.1124/mol.112.080408. Epub 2012 Sep 18.

PMID:
22989521
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

PMID:
18606717
[PubMed - indexed for MEDLINE]
Free Article
9.

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.

Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.

Int J Cancer. 2013 Aug 15;133(4):984-96. doi: 10.1002/ijc.28073. Epub 2013 Mar 8.

PMID:
23475782
[PubMed - indexed for MEDLINE]
10.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.

PMID:
23954373
[PubMed - indexed for MEDLINE]
11.

The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.

Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S.

Neoplasia. 2012 Jan;14(1):34-43.

PMID:
22355272
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.

Mol Cancer Ther. 2009 Aug;8(8):2204-10. doi: 10.1158/1535-7163.MCT-09-0160. Epub 2009 Aug 11.

PMID:
19671762
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

PMID:
21712451
[PubMed - indexed for MEDLINE]
Free Article
14.

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.

Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O.

Mol Cancer. 2011 Jul 26;10:90. doi: 10.1186/1476-4598-10-90.

PMID:
21791089
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.

PMID:
23705826
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.

Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.

Int J Mol Med. 2013 Jun;31(6):1449-56. doi: 10.3892/ijmm.2013.1351. Epub 2013 Apr 16.

PMID:
23588698
[PubMed - indexed for MEDLINE]
17.

Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.

Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL.

Toxicol Lett. 2013 Jul 18;220(3):267-76. doi: 10.1016/j.toxlet.2013.04.021. Epub 2013 May 4.

PMID:
23651616
[PubMed - indexed for MEDLINE]
18.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.

PMID:
18829560
[PubMed - indexed for MEDLINE]
Free Article
19.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P.

PLoS One. 2012;7(1):e29925. doi: 10.1371/journal.pone.0029925. Epub 2012 Jan 27.

PMID:
22299028
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.

Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, Cheung CS, Ho K, Chan AT.

Cancer Lett. 2014 Feb 1;343(1):24-32. doi: 10.1016/j.canlet.2013.09.007. Epub 2013 Sep 14.

PMID:
24041865
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk